Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance

Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in clinical practice. Here we investigated the mechanisms underlying acquired bortezomib resistance in hepatocellular carcinoma (HCC) cells. Using stepwise selection, we established two acquired bortezomib-resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Xin, Yang, Jia-Hua, Saitsu, Hirotomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363609/
https://www.ncbi.nlm.nih.gov/pubmed/27769058
http://dx.doi.org/10.18632/oncotarget.12731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363609/
https://www.ncbi.nlm.nih.gov/pubmed/27769058
http://dx.doi.org/10.18632/oncotarget.12731

Ejemplares similares